VRNA insider transaction filings
Verona Pharma plc — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-10-08. Screen VRNA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-08 | 4 | Ullman Anders — Director | Disposition to issuer (D): 358,856 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | Fisher Andrew — General Counsel | Disposition to issuer (D): 417,903 · Option exercise (M): 931,984 · Disposition to issuer (D): 931,984 · Option exercise (M): 146,168 (derivative) · Option exercise (M): 167,056 (derivative) · Grant/award (A): 618,760 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | Rickard Kathleen A. — Chief Medical Officer | Disposition to issuer (D): 2,432,868 · Option exercise (M): 1,131,984 · Disposition to issuer (D): 1,131,984 · Option exercise (M): 146,168 (derivative) · Option exercise (M): 167,056 (derivative) · Option exercise (M): 200,000 (derivative) · +4 more | EDGAR |
| 2025-10-08 | 4 | Austwick Michael — Director | Disposition to issuer (D): 12,712 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 144,000 (derivative) | EDGAR |
| 2025-10-08 | 4 | Deschamps Lisa — Director | Disposition to issuer (D): 84,856 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | Brady James Aloysius — Director | Disposition to issuer (D): 23,176 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 288,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +1 more | EDGAR |
| 2025-10-08 | 4 | Cunningham Kenneth — Director | Disposition to issuer (D): 79,776 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | ACKERMANN CHRISTINA — Director | Disposition to issuer (D): 64,072 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 144,000 (derivative) | EDGAR |
| 2025-10-08 | 4 | Edwards Martin — Director | Disposition to issuer (D): 157,992 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Disposition to issuer (D): 12,176,144 · Option exercise (M): 3,285,280 · Disposition to issuer (D): 3,285,280 · Option exercise (M): 800,000 (derivative) · Option exercise (M): 389,792 (derivative) · Option exercise (M): 445,536 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | Hahn Mark W — Chief Financial Officer | Disposition to issuer (D): 11,264,968 · Option exercise (M): 3,285,280 · Disposition to issuer (D): 3,285,280 · Option exercise (M): 800,000 (derivative) · Option exercise (M): 389,792 (derivative) · Option exercise (M): 445,536 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | Sinha Vikas — Director | Disposition to issuer (D): 94,112 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 384 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | SHAH MAHENDRA — Director | Disposition to issuer (D): 93,472 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Option exercise (M): 72,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) · Disposition to issuer (D): 96,000 (derivative) · +2 more | EDGAR |
| 2025-10-08 | 4 | EBSWORTH DAVID R — Director | Disposition to issuer (D): 880,499 · Option exercise (M): 72,000 · Disposition to issuer (D): 72,000 · Disposition to issuer (D): 617,600 · Option exercise (M): 72,000 (derivative) | EDGAR |
| 2025-09-03 | 4 | Rickard Kathleen A. — Chief Medical Officer | Gift (G): 189,600 @ $0 | EDGAR |
| 2025-09-03 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Gift (G): 1,200,000 @ $0 | EDGAR |
| 2025-09-03 | 4 | Hahn Mark W — Chief Financial Officer | Gift (G): 1,200,000 @ $0 | EDGAR |
| 2025-08-05 | 4 | Cunningham Kenneth — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 10,808 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Deschamps Lisa — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 9,464 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Fisher Andrew — General Counsel | Option exercise (M): 20,888 @ $0 · Sale (S): 9,584 @ $13.14 · Option exercise (M): 20,888 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Rickard Kathleen A. — Chief Medical Officer | Option exercise (M): 70,888 @ $0 · Sale (S): 58,336 @ $13.14 · Option exercise (M): 50,000 (derivative) @ $0 · Option exercise (M): 20,888 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | ACKERMANN CHRISTINA — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 1,808 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Austwick Michael — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 11,288 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Brady James Aloysius — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 824 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Ullman Anders — Director | Option exercise (M): 24,000 @ $0 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Edwards Martin — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 10,808 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Option exercise (M): 255,696 @ $0 · Sale (S): 208,912 @ $13.14 · Option exercise (M): 200,000 (derivative) @ $0 · Option exercise (M): 55,696 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Hahn Mark W — Chief Financial Officer | Option exercise (M): 255,696 @ $0 · Sale (S): 208,912 @ $13.14 · Option exercise (M): 200,000 (derivative) @ $0 · Option exercise (M): 55,696 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | Sinha Vikas — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 4,328 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | SHAH MAHENDRA — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 3,608 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-08-05 | 4 | EBSWORTH DAVID R — Director | Option exercise (M): 24,000 @ $0 · Sale (S): 1,904 @ $13.14 · Option exercise (M): 24,000 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Rickard Kathleen A. — Chief Medical Officer | Option exercise (M): 86,064 @ $0 · Tax withholding (F): 37,616 @ $11.44 · Grant/award (A): 253,120 (derivative) @ $0 · Option exercise (M): 86,064 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Fisher Andrew — General Counsel | Option exercise (M): 86,064 @ $0 · Tax withholding (F): 39,464 @ $11.44 · Grant/award (A): 253,120 (derivative) @ $0 · Option exercise (M): 86,064 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Option exercise (M): 229,512 @ $0 · Tax withholding (F): 90,320 @ $11.44 · Grant/award (A): 675,048 (derivative) @ $0 · Option exercise (M): 229,512 (derivative) @ $0 | EDGAR |
| 2025-07-09 | 4 | Hahn Mark W — Chief Financial Officer | Option exercise (M): 229,512 @ $0 · Tax withholding (F): 90,320 @ $11.44 · Grant/award (A): 675,048 (derivative) @ $0 · Option exercise (M): 229,512 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Fisher Andrew — General Counsel | Option exercise (M): 80,000 @ $2.01 · Sale (S): 80,000 @ $11.53 · Option exercise (M): 80,000 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4/A | Fisher Andrew — General Counsel | Option exercise (M): 80,000 @ $2.01 · Option exercise (M): 80,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Sale (S): 400,000 @ $11.40 | EDGAR |
| 2025-06-13 | 4 | Hahn Mark W — Chief Financial Officer | Sale (S): 400,000 @ $11.40 | EDGAR |
| 2025-05-29 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Sale (S): 33,600 @ $9.53 · Sale (S): 157,704 @ $9.30 · Sale (S): 208,696 @ $9.33 | EDGAR |
| 2025-05-29 | 4 | Hahn Mark W — Chief Financial Officer | Sale (S): 32,432 @ $9.53 · Sale (S): 162,704 @ $9.30 · Sale (S): 204,864 @ $9.33 | EDGAR |
| 2025-05-22 | 4 | Sinha Vikas — Director | Option exercise (M): 160,000 @ $0.50 · Sale (S): 160,000 @ $9.39 · Option exercise (M): 160,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4/A | Sinha Vikas — Director | Option exercise (M): 120,384 @ $1.70 · Sale (S): 120,384 @ $8.92 · Option exercise (M): 39,616 @ $0.50 · Sale (S): 39,616 @ $8.92 · Option exercise (M): 120,384 (derivative) @ $0 · Option exercise (M): 39,616 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Fisher Andrew — General Counsel | Option exercise (M): 80,000 @ $2.11 · Sale (S): 80,000 @ $8.57 · Option exercise (M): 80,000 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | ACKERMANN CHRISTINA — Director | Option exercise (M): 40,000 @ $1.93 · Sale (S): 40,000 @ $8.44 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2025-05-08 | 4 | Rickard Kathleen A. — Chief Medical Officer | Sale (S): 114,984 @ $8.82 | EDGAR |
| 2025-05-05 | 4 | Rickard Kathleen A. — Chief Medical Officer | Sale (S): 27,336 @ $8.95 · Option exercise (M): 50,000 · Sale (S): 21,864 @ $8.95 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | ZACCARDELLI DAVID — President and CEO, Director | Sale (S): 108,272 @ $8.95 · Option exercise (M): 200,000 · Sale (S): 78,736 @ $8.95 · Sale (S): 400,000 @ $9.09 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | Hahn Mark W — Chief Financial Officer | Sale (S): 108,272 @ $8.95 · Option exercise (M): 200,000 · Sale (S): 78,736 @ $8.95 · Sale (S): 400,000 @ $9.09 · Option exercise (M): 200,000 (derivative) @ $0 | EDGAR |
| 2025-05-05 | 4 | EBSWORTH DAVID R — Director | Option exercise (M): 140,000 @ $1.93 · Option exercise (M): 140,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Verona Pharma plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-10-07 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-09 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-09 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-25 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-03-28 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=VRNA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →